Notice 01

For laboratory and research use only. Not for human consumption or therapeutic use.

ISO 9001 · GMP sourced

About

We built the supplier
we wanted to exist.

Alvar Peptides was started in 2024 by a small group of chemists who had spent too long reading marketing language where a chromatogram should have been. We make research peptides for the people who actually read the report.

01 · What we won't do

Four lines
we don't cross.

  1. I.

    We do not downgrade failed lots.

    If a batch doesn't meet the ≥ 99.0% floor, it is destroyed — not relabeled, not sold at discount, not rerouted through a shell brand. The only way a vial leaves our facility is if it passed.

  2. II.

    We do not test our own purity.

    Every lot goes to an accredited, unaffiliated laboratory for HPLC and mass-spectrometry verification. The COA that ships with your vial carries the external lab's letterhead, not ours.

  3. III.

    We do not ship at room temperature.

    Every shipment moves under continuous 2 – 8 °C cold-chain with a data logger inside the package. If the log shows an excursion beyond 25 °C for more than 48 hours, we replace the order without a claims process.

  4. IV.

    We do not sell outside the research context.

    Accounts are issued only to licensed institutions, accredited laboratories, and qualified independent researchers. Verification happens once, at onboarding, and before the first shipment moves.

02 · Origin

A short history.

Alvar is a young company, and we'd rather be honest about what's already happened than invent a longer past.

  1. 2024 · Q1

    Founded

    Ines Alvar incorporates Alvar Peptides BV in Rotterdam. Synthesis partnership signed with a GMP-sourced contract facility in Leiden.

  2. 2024 · Q3

    First verified lots ship

    BPC-157, TB-500, Ipamorelin ship with third-party HPLC reports from Janošik Analytical.

  3. 2025 · Q2

    Wilmington fulfillment

    Second cold-chain node opens in Wilmington, DE to serve North American research accounts directly.

  4. 2025 · Q4

    Expanded catalog

    Nootropic, cosmetic, and longevity categories added. Lot-scan QR verification deployed across all shipments.

  5. 2026 · Q2

    Custom synthesis

    Tier III program opens for bespoke sequences and multi-gram quantities, with four-week lead times.

03 · Team

Small, for now.

  • Ines Alvar

    Founder · Head of Synthesis

    Twelve years at CRO-scale peptide synthesis before founding Alvar. PhD, chemistry, Leiden.

  • Jonah Voerman

    QC Lead · Signatory

    Prior QC at two pharmaceutical GMP facilities. Signs off every outbound lot after third-party review.

  • Mira Chen

    Research Liaison

    Onboards institutional accounts, handles protocol questions, and routes custom-synthesis enquiries.

  • Antti Laine

    Logistics & Cold-chain

    Owns the data-logged cold-chain, from fulfillment nodes to destination verification and excursion replacement.

04 · Locations

Two cities,
one standard.

Headquarters · NL

Rotterdam

Entity
Alvar Peptides BV · KVK 0000000
Role
Synthesis partnership, QC coordination, EU / UK / APAC fulfillment
Address
Wilhelminakade 00 · 3072 AP Rotterdam
Fulfillment · US

Wilmington, DE

Role
North American cold-chain fulfillment
Opened
2025
Capacity
Direct ship to 34 US states and Canada

Access

Ready to open
an account?

Apply once. Orders thereafter route through your verified research account. Typical onboarding: one business day.

Request access →